Azacitidine is well tolerated in the majority of patients with acute myeloid leukemia after allogeneic stem cell transplantation.
Administration of post-transplantation azacitidine is associated with a low risk of chronic graft-versus-host disease.
Patients who demonstrate a CD8+ T cell response to tumor antigens demonstrate a lower risk of relapse.